Cargando…

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates "reverse" cholesterol transport and reduce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tenenbaum, Alexander, Motro, Michael, Fisman, Enrique Z
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1236941/ https://www.ncbi.nlm.nih.gov/pubmed/16168052 http://dx.doi.org/10.1186/1475-2840-4-14

Ejemplares similares

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
por: Tenenbaum, Alexander, et al.
Publicado: (2008)

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment
por: Node, Koichi, et al.
Publicado: (2009)

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer
por: Huang, Runzhi, et al.
Publicado: (2020)

The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome
por: Huang, Yan, et al.
Publicado: (2017)

Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats
por: Khazaei, M., et al.
Publicado: (2012)

Losartan and diabetic nephropathy: commentaries on the RENAAL study
por: Fisman, Enrique Z, et al.
Publicado: (2002)

Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof
por: Fisman, Enrique Z, et al.
Publicado: (2003)

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
por: Arbel, Yaron, et al.
Publicado: (2016)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

Oxaliplatin Neurotoxicity Involves Peroxisome Alterations. PPARγ Agonism as Preventive Pharmacological Approach
por: Zanardelli, Matteo, et al.
Publicado: (2014)

Myelin Disruption, Neuroinflammation, and Oxidative Stress Induced by Sulfite in the Striatum of Rats Are Mitigated by the pan-PPAR agonist Bezafibrate
por: Glänzel, Nícolas Manzke, et al.
Publicado: (2023)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures
por: Oyama, Takuji, et al.
Publicado: (2009)

Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model
por: Saha, Lekha, et al.
Publicado: (2014)

Key Issues in the Role of Peroxisome Proliferator–Activated Receptor Agonism and Cell Signaling in Trichloroethylene Toxicity
por: Keshava, Nagalakshmi, et al.
Publicado: (2006)

Peroxisome Proliferator–Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia
por: Mulvey, Claire K., et al.
Publicado: (2012)

Downregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposis
por: Cardell, Lars-Olaf, et al.
Publicado: (2005)

Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders
por: Cho, Min-Chul, et al.
Publicado: (2008)

Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Trophoblast Functions
por: Peng, Lin, et al.
Publicado: (2021)

Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro
por: Alexander, Stephen PH, et al.
Publicado: (2012)

Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
por: Samuelsson, O., et al.
Publicado: (2013)

Sinapic acid attenuates cisplatin-induced nephrotoxicity through peroxisome proliferator-activated receptor gamma agonism in rats
por: Singh, Hardevinder Pal, et al.
Publicado: (2020)

Expression of the Peroxisome Proliferator-Activated Receptors (PPARs) in the Hepatic Stellate Cells
por: Sato, Takeya, et al.
Publicado: (2004)

Peroxisome Proliferator-Activated Receptor (PPAR): Balance for Survival in Parasitic Infections
por: Chan, Marion M., et al.
Publicado: (2010)

Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2018)

Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Mechanisms Involved in the Enhanced Susceptibility of Senescent Rats to the Hepatocarcinogenic Effect of Peroxisome Proliferators: Role of Peroxisome Proliferator-Activated Receptor alpha (PPAR), Cell Proliferation and Oxidative Stress
por: Youssef, Jihan A., et al.
Publicado: (2001)

Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic Disorders
por: Ren, Ping, et al.
Publicado: (2015)

Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy
por: Gou, Qian, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptors (PPARs) and Oxidative Stress in Physiological Conditions and in Cancer
por: Muzio, Giuliana, et al.
Publicado: (2021)

Effect of Pesticides on Peroxisome Proliferator-Activated Receptors (PPARs) and Their Association with Obesity and Diabetes
por: Hernández-Valdez, J., et al.
Publicado: (2023)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours
por: Marques, A R, et al.
Publicado: (2004)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice
por: Michalik, Liliane, et al.
Publicado: (2001)

Diverse coactivator recruitment through differential PPARγ nuclear receptor agonism
por: Lizcano, Fernando, et al.
Publicado: (2013)

Obese Mice Lacking Inducible Nitric Oxide Synthase Are Sensitized to the Metabolic Actions of Peroxisome Proliferator–Activated Receptor-γ Agonism
por: Dallaire, Patrice, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ai35id5d2uh8kgap4ggjfergn4